Lerna Biopharma is a preclinical stage biopharmaceutical company developing RNA therapeutics for patients with liver diseases. Lerna Bio harnesses the intrinsic regenerative potential of liver through RNA technology, providing solutions for patients lacking treatment options. Our innovation was borne from Dr. Torsten Wuestefeld’s Quartz target identification platform, a versatile in vivo in vivo functional genomics screen that generates a pipeline of targets for liver diseases. and beyond. Our lead asset is a first-in-class GalNAc-siRNA that enhances liver regeneration to boost liver functions in cirrhotic patients. 

With sites in Singapore, China and USA, Lerna Bio leverages our chemistry and biological insights to deliver clinically meaningful treatments.